Clinical Trial Update: Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial is evaluating adding daratumumab to standard chemotherapy for newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Children's Oncology Group | Conditions: Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING